• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by SciSparc Ltd.

    3/6/24 5:02:18 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRC alert in real time by email
    SC 13G 1 tm248112d1_sc13.htm FORM 13-G

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    SciSparc Ltd.

    (Name of Issuer)

     

     

     

    Ordinary Shares, no par value

    (Title of Class of Securities)

     

    M82618113

    (CUSIP Number)

     

    February 27, 2024

    (Date of Event, which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨       Rule 13d-1(b)

    x       Rule 13d-1(c)

    ¨       Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information, which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act out shall be subject to all other provisions of the Act, (however, see the Notes).

     

     

     

     

     

     

     

    CUSIP No. M82618113

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
    YA II PN, Ltd.

    (98-0615462)

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Cayman Islands
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
    6 Shared Voting Power: 115,482*
         
    7. Sole Dispositive Power: 0
         
    8. Shared Dispositive Power: 115,482*
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:   115,482*
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):        9.99%**
         
      12. Type of Reporting Person (See Instructions):     OO

     

    * 115,482 Oridnary Shares, no par value per share (“Ordinary Shares”) of SciSparc Ltd. (the “Issuer”) consisting of the direct ownership of 55,293 Ordinary Shares and the deemed ownership of 60,189 additional Ordinary Shares that the reporting person has the right to acquire within 60 days of the date of the report.

     

    ** Calculation based on 1,155,973 outstanding Ordinary Shares, consisting of 1,095,784 Ordinary Shares outstanding as of February 27, 2024 as reported by the Issuer in its Registration Statement on Form F-1 filed with the U.S. Securities and Exchange Commission on February 27, 2024 (the “Form F-1”) and an additional 60,189 Ordinary Shares that the reporting person has the right to acquire within 60 days of the date of the report.

     

     

     

     

    CUSIP No. M82618113

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
        YA Global Investments II (U.S.), LP
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Cayman Islands
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
    6 Shared Voting Power: 115,482*
         
    7. Sole Dispositive Power: 0
         
    8. Shared Dispositive Power: 115,482*
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:  115,482*
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         9.99%**
         
      12. Type of Reporting Person (See Instructions):     OO

     

    * 115,482 Oridnary Shares of the Issuer consisting of the direct ownership of 55,293 Ordinary Shares and the deemed ownership of 60,189 additional Ordinary Shares that the reporting person has the right to acquire within 60 days of the date of the report.

     

    ** Calculation based on 1,155,973 outstanding Ordinary Shares, consisting of 995,907 Ordinary Shares outstanding as of February 27, 2024 as reported by the Issuer in its Form F-1 and an additional 60,189 Ordinary Shares that the reporting person has the right to acquire within 60 days of the date of the report.

     

     

     

     

    CUSIP No. M82618113

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
        Yorkville Advisors Global, LP
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Cayman Islands
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
    6 Shared Voting Power: 115,482*
         
    7. Sole Dispositive Power: 0
         
    8. Shared Dispositive Power: 115,482*
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:  115,482*
         
      10. Check if the Aggregate Amount in Row (9)  Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         9.99%**
         
      12. Type of Reporting Person (See Instructions):     OO

     

    * 115,482 Oridnary Shares of the Issuer consisting of the direct ownership of 55,293 Ordinary Shares and the deemed ownership of 60,189 additional Ordinary Shares that the reporting person has the right to acquire within 60 days of the date of the report.

     

    ** Calculation based on 1,155,973 outstanding Ordinary Shares, consisting of 995,907 Ordinary Shares outstanding as of February 27, 2024 as reported by the Issuer in its Form F-1 and an additional 60,189 Ordinary Shares that the reporting person has the right to acquire within 60 days of the date of the report.

     

     

     

     

    CUSIP No. M82618113

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
        Yorkville Advisors Global II, LLC
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Cayman Islands
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
    6 Shared Voting Power: 115,482*
         
    7. Sole Dispositive Power: 0
         
    8. Shared Dispositive Power: 115,482*
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:   115,482*
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         9.99%**
         
      12. Type of Reporting Person (See Instructions):     OO

     

    * 115,482 Oridnary Shares of the Issuer consisting of the direct ownership of 55,293 Ordinary Shares and the deemed ownership of 60,189 additional Ordinary Shares that the reporting person has the right to acquire within 60 days of the date of the report.

     

    ** Calculation based on 1,155,973 outstanding Ordinary Shares, consisting of 995,907 Ordinary Shares outstanding as of February 27, 2024 as reported by the Issuer in its Form F-1 and an additional 60,189 Ordinary Shares that the reporting person has the right to acquire within 60 days of the date of the report.

     

     

     

     

    CUSIP No. M82618113

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
        YA II GP, LP
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Cayman Islands
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
    6 Shared Voting Power: 115,482*
         
    7. Sole Dispositive Power: 0
         
    8. Shared Dispositive Power: 115,482*
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:   115,482*
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         9.99%**
         
      12. Type of Reporting Person (See Instructions):     OO

     

    * 115,482 Oridnary Shares of the Issuer consisting of the direct ownership of 55,293 Ordinary Shares and the deemed ownership of 60,189 additional Ordinary Shares that the reporting person has the right to acquire within 60 days of the date of the report.

     

    ** Calculation based on 1,155,973 outstanding Ordinary Shares, consisting of 995,907 Ordinary Shares outstanding as of February 27, 2024 as reported by the Issuer in its Form F-1 and an additional 60,189 Ordinary Shares that the reporting person has the right to acquire within 60 days of the date of the report.

     

     

     

     

    CUSIP No. M82618113

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
        YAII GP II, LLC
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Cayman Islands
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
    6 Shared Voting Power: 115,482*
         
    7. Sole Dispositive Power: 0
         
    8. Shared Dispositive Power: 115,482*
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:   115,482*
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         9.99%**
         
      12. Type of Reporting Person (See Instructions):     OO

     

    * 115,482 Oridnary Shares of the Issuer consisting of the direct ownership of 55,293 Ordinary Shares and the deemed ownership of 60,189 additional Ordinary Shares that the reporting person has the right to acquire within 60 days of the date of the report.

     

    ** Calculation based on 1,155,973 outstanding Ordinary Shares, consisting of 995,907 Ordinary Shares outstanding as of February 27, 2024 as reported by the Issuer in its Form F-1 and an additional 60,189 Ordinary Shares that the reporting person has the right to acquire within 60 days of the date of the report.

     

     

     

     

    CUSIP No. M82618113

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
        Mark Angelo
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Cayman Islands
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
    6 Shared Voting Power: 115,482*
         
    7. Sole Dispositive Power: 0
         
    8. Shared Dispositive Power: 115,482*
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:  115,482*
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         9.99%**
         
      12. Type of Reporting Person (See Instructions):     OO

     

    * 115,482 Oridnary Shares of the Issuer consisting of the direct ownership of 55,293 Ordinary Shares and the deemed ownership of 60,189 additional Ordinary Shares that the reporting person has the right to acquire within 60 days of the date of the report.

     

    ** Calculation based on 1,155,973 outstanding Ordinary Shares, consisting of 995,907 Ordinary Shares outstanding as of February 27, 2024 as reported by the Issuer in its Form F-1 and an additional 60,189 Ordinary Shares that the reporting person has the right to acquire within 60 days of the date of the report. 

     

     

     

     

    CUSIP No. M82618113

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
        SC-Sigma Global Partners, LP
    84-5173620
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Delaware
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
    6 Shared Voting Power: 115,482*
         
    7. Sole Dispositive Power: 0
         
    8. Shared Dispositive Power: 115,482*
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:  115,482*
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         9.99%**
         
      12. Type of Reporting Person (See Instructions):     OO

     

    * 115,482 Oridnary Shares of the Issuer consisting of the direct ownership of 55,293 Ordinary Shares and the deemed ownership of 60,189 additional Ordinary Shares that the reporting person has the right to acquire within 60 days of the date of the report.

     

    ** Calculation based on 1,155,973 outstanding Ordinary Shares, consisting of 995,907 Ordinary Shares outstanding as of February 27, 2024 as reported by the Issuer in its Form F-1 and an additional 60,189 Ordinary Shares that the reporting person has the right to acquire within 60 days of the date of the report.

     

     

     

     

    Item 1.

     

      (a) Name of Issuer:

    SciSparc Ltd.

     

      (b) Address of Issuer’s Principal Executive Offices:

    20 Raul Wallenberg Street, Tower A

    Tel Aviv 6971916, Israel

     

    Item 2. Identity and Background.

     

      (a) Name of Person Filing:

    YA II PN, Ltd.

     

      (b) Address of Principal Executive Office or, if none, Residence of Reporting Persons:

    1012 Springfield Ave.

    Mountainside, NJ 07092

     

      (c) Citizenship:

    Cayman Islands

     

      (d) Title of Class of Securities:

    Ordinary Shares, no par value per share

     

      (e) CUSIP Number:

    M82618113

     

    Item 3. If the statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is:

     

    (a) ¨  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b) ¨  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c) ¨  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d) ¨  Investment company registered under section 8 of the Investment Company Act of 1940 (15 of the Act (15 U.S.C. 78o);
    (e) ¨  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f) ¨  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g) ¨  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
    (h) ¨  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) ¨  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) ¨  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); or
    (k) x  Group, in accordance with 240.13d(b)(1)(ii)(K).

     

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

     

      (a) Amount beneficially owned: 115,482*

     

      (b) Percentage of Class: 9.99%**

     

     

     

     

      (c) Number of shares as to which the person has:

     

      (i) Sole Power to vote or to direct the vote: 0

     

      (ii) Shared power to vote or to direct the vote: 115,482

     

      (iii) Sole power to dispose or to direct the disposition: 0

     

      (iv) Shared power to dispose or to direct the disposition: 115,482

     

    * 115,482 Oridnary Shares of the Issuer consisting of the direct ownership of 55,293 Ordinary Shares and the deemed ownership of 60,189 additional Ordinary Shares that the reporting person has the right to acquire within 60 days of the date of the report.

     

    ** Calculation based on 1,155,973 outstanding Ordinary Shares, consisting of 995,907 Ordinary Shares outstanding as of February 27, 2024 as reported by the Issuer in its Form F-1 and an additional 60,189 Ordinary Shares that the reporting person has the right to acquire within 60 days of the date of the report.

     

    Item 5. Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Item 6. Ownership of more than five percent on Behalf of Another Person.

     

    The reporting persons directly or indirectly own an aggregate of 115,482 Class A Shares of the Issuer, or 9.99% of such class of stock as of the date of this filing.

     

    Direct beneficial ownership of such Class A Shares by the reporting persons is as follows (and therefore excludes any Class A Shares indirectly held by such person or any securities, such as warrants, which may be exercised or converted into Class A Shares of the Company):

     

      · YA II PN, Ltd. – 55,293

     

      · YA Global Investments II (U.S.), LP – 0

     

      · Yorkville Advisors Global, LP – 0

     

      · Yorkville Advisors Global II, LLC – 0

     

      · YA II GP, LP – 0

     

      · YAII GP II, LLC – 0

     

      · Mark Angelo – 0

     

      · SC-Sigma Global Partners, LP – 0

     

    Indirect beneficial ownership: YA II PN, Ltd. (“YA II”) entered into a Standby Equity Purchase Agreement (“SEPA”) with SciSparc Ltd., dated as of January 21, 2024, which was amended as of Ferbuary 27, 2024. Under the SEPA, the Issuer has the option to sell up to $20 million of its Oridnary Shares to YA II, and YA II is obligated to purchase such shares, at a price and on the terms and subject to the conditions set forth in the SEPA. Under the SEPA, the Issuer is prohibited from issuing and selling shares to YA II to the extent that it would cause the aggregate number of Ordinary Shares beneficially owned by YA II and its affiliates to exceed 9.99% of the outstanding Ordinary Shares of the Issuer. In connection with the SEPA, The Issuer has issued to YA II 55,293 Ordinary Shares in satisfaction of payment of the commitment fee set forth in the SEPA.

     

     

     

     

    In addition to the direct beneficial ownership set forth above, each reporting person is also deemed to be the indirect beneficial owner of 60,189 additional Ordinary Shares that the reporting persons may acquire under the SEPA within 60 days of the date of this filing.

     

    Below is a description of the relationship among the reporting persons:

     

    YA II PN, Ltd. (“YA II”) is beneficially owned by YA Global Investments II (U.S.), LP (the “YA Feeder”). Yorkville Advisors Global, LP (the “YA Advisor”) is the investment manager to YA II. Yorkville Advisors Global II, LLC (the “YA Advisor GP”) is the general partner to the YA Advisor. YAII GP, LP (the “YA GP”) is the general partner to the YA Feeder. YAII GP II, LLC (the “Yorkville GP”) is the general partner to the YA GP. Mark Angelo makes the investment decisions on behalf of YA II. Accordingly, each of YA II, YA Feeder, the YA Advisor, the YA Advisor GP, the YA GP, the Yorkville GP and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of Class A Shares.

     

    YA II GP, LP is the general partner of SC-Sigma Global Partners, LP (“SC-Sigma”), which is an investor in YA II. YAII GP II, LLC is the general partner of YA II GP, LP. The YA Advisor is the investment manager to SC-Sigma. Accordingly, SC-Sigma, the YA GP, the Yorkville GP, the YA Advisor, and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of shares of Class A Shares.

     

    For purposes of this filing, each of the reporting persons is deemed an affiliate of each other reporting person.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not Applicable

     

    Item 8. Identification and Classification of Member Group

     

    See Item 6.

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable

     

    Item 10. Certification

     

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as participant in any transaction having that purpose or effect.

     

    Additional Information:

     

    Each Reporting Person disclaims beneficial ownership of any securities beneficially owned by each other Reporting Person, and its report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of these securities for the purpose of Section 16 or for any other purpose.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement in true, complete and correct.

     

      REPORTING PERSON:  
         
    Dated: March 6, 2024  
     
      REPORTING PERSON:
     
    YA II PN, Ltd.  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  
       
    YA Global Investments II (U.S.), LP  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  
       
    Yorkville Advisors Global, LP  
       
    By: Yorkville Advisors Global, LLC  
    Its: General Partner  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  
       
    Yorkville Advisors Global II, LLC  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  
       
    YA II GP, LP  
       
    By: YAII GP II, LLC  
    Its: General Partner  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  
       
    YAII GP II, LLC  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  

     

     

    SC-Sigma Global Partners, LP
     
    By: /s/ Robert Munro
      Robert Munro
      Chief Compliance Officer

     

     

     

    Get the next $SPRC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SPRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SPRC
    Leadership Updates

    Live Leadership Updates

    See more
    • SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP

      As part of the Company's corporate restructuring plan, Mr. Yaki Baranes will facilitate identifying new business opportunities TEL AVIV, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that as part of its restructuring plans to unlock value for shareholders, it has appointed a new Vice President of Strategy and Business Development, Mr. Yaki Baranes, to structure business strategies and facilitate identifying new business opportunities. Mr. Baranes is a business strategy expert with a

      5/30/23 8:40:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins

      JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the appointment of Prof. Ciro Leonardo Pierri as special advisor for MitoCareX Bio Ltd. ("MitoCareX Bio"), SciSparc's recently established joint venture ("JV") for the discovery and development of potential drugs for cancers, infectious diseases and other life-threatening conditions. Prof. Pierri is a biochemist and serves as an associate professor at the U

      6/15/22 8:30:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain

      Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced the appointment of Professor Avi Schroeder as a member of the Company's Scientific Advisory Board (SAB). As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroed

      3/30/22 8:30:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by SciSparc Ltd.

      SC 13G - SciSparc Ltd. (0001611746) (Subject)

      3/6/24 5:02:18 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by SciSparc Ltd.

      SC 13G - SciSparc Ltd. (0001611746) (Filed by)

      12/13/22 6:22:30 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by SciSparc Ltd. (Amendment)

      SC 13G/A - SciSparc Ltd. (0001611746) (Subject)

      5/9/22 4:08:30 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRC
    SEC Filings

    See more
    • Amendment: SEC Form F-4/A filed by SciSparc Ltd.

      F-4/A - SciSparc Ltd. (0001611746) (Filer)

      4/28/25 7:11:58 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by SciSparc Ltd.

      S-8 - SciSparc Ltd. (0001611746) (Filer)

      4/28/25 8:56:08 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by SciSparc Ltd.

      6-K - SciSparc Ltd. (0001611746) (Filer)

      4/25/25 8:19:42 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRC
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SPRC
    Financials

    Live finance-specific insights

    See more
    • SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

      TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) has led to the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders. The patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with SciSparc's Palmitoylethanolamide ("PEA"). This innovative combination aims to address the complex neurobiological and psych

      4/25/25 7:59:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

      TEL AVIV, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) has led to the publication of a patent application by the South Korean Intellectual Property Office ("KIPO"). The patent application relates to a combination treatment using Clearmind's 5-methoxy-2-aminoindane ("MEAI") and SciSparc's Palmitoylethanolamide ("PEA") for the treatment of cocaine addiction. The patent is based on preclinical trial results led by P

      3/10/25 7:45:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

      Vancouver, Canada, March 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a patent by the Korean Intellectual Property Office (KIPO), South Korea's official patent and intellectual property authority. The patent covers the Company's innovative combination therapy of MEAI and N-Acylethanolamines for the treatment of cocaine addiction. The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Mu

      3/10/25 7:27:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Adopts Limited Duration Shareholder Rights Plan

      TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its Board of Directors (the "Board") has unanimously adopted a limited duration shareholder rights plan (the "Rights Plan"), effective immediately. "Today we announced exciting positive results from our weight loss and metabolic disorder program with our proprietary psychedelic-based treatment," said Oz Adler, SciSparc's Chief Executive Officer. "Unfortunately, SciSparc, like many other clinical-stag

      11/28/23 8:55:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel

      SciSparc seeks to scale up revenues and will consider transferring its pharmaceutical activities to a separate legal entity and exploring the possibility of dividend distribution TEL AVIV, Israel, Nov. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the signing of a non-binding letter of intent to merge with a leading vehicle importer company in Israel (the "Target Company"). This merger (the "Merger) is expected to be consummated by means of a reverse triangular merger, pursua

      11/22/23 7:42:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split

      Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and outstanding TEL AVIV, Israel, Sept. 27, 2023 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announces today that its previously announced reverse share split of its issued and outstanding ordinary shares, no par value at a ratio of 1-for-26, is expected to be implemented after market close today. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at

      9/27/23 7:58:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care